Real estate
The new state-of-the-art facility, dubbed the “Factory of the Future,” will span 110,000 square feet and will be located in the city of Wilsonville, Oregon.
The company is significantly expanding its footprint with new facilities in the United States and in Europe.
Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.
Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.
Pfizer is continuing to invest in gene therapy research and development and other areas going on throughout the company, specifically in its North Carolina sites in Chapel Hill and Kit Creek.
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.
The expansion is part of the company’s acquisition of a 500,000-square-foot property that Aphena will renovate “into a state-of-the-art pharmaceutical and packaging and distribution facility.”
The new facility will be 14,000 square feet and is designed from start to finish to meet global current Good Manufacturing Practice (cGMP) standards for radiopharmaceutical manufacturing.
PRESS RELEASES